41926-18-5

Usage

Uses

Used in Pharmaceutical Synthesis:
5-CHLORO-7-NITRO (1H)INDAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic benefits in different areas of medicine.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-CHLORO-7-NITRO (1H)INDAZOLE serves as a crucial building block for the creation of new agrochemicals. Its properties contribute to the development of effective products for crop protection and other agricultural applications.
Used in Organic Synthesis:
5-CHLORO-7-NITRO (1H)INDAZOLE is utilized as a versatile building block in organic synthesis. Its chemical properties enable the modification and creation of a variety of derivatives with different functionalities, expanding its potential applications in various fields.
Used in Drug Discovery and Development:
Due to its potential biological activity, 5-CHLORO-7-NITRO (1H)INDAZOLE is investigated for its use as a drug candidate in various therapeutic areas. Its unique structure and properties make it a promising compound for the development of new treatments and therapies.
Used in Research and Development:
5-CHLORO-7-NITRO (1H)INDAZOLE is employed in research and development efforts to explore its potential applications and properties. Its unique chemical structure and potential biological activity make it an interesting subject for scientific investigation and the development of new technologies and products.

Upstream product

• 570-24-1 2-Methyl-6-nitroaniline 
• 62790-50-5 4-chloro-2-methyl-6-nitrophenylamine 

Downstream Products

• 221681-89-6 7-amino-5-chloroindazole 

Relevant academic research and scientific papers

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Research in 7-aminoindazole series: Synthesis of new halo-7H-4-methylpyrazolo[1,5,4-ef][1,5]benzodiazepin-6-ones and 5H-9-halo-6-methylpyrazolo[1,5,4-ef][1,5]benzodiazepin-4-ones

A new class of 7-aminohaloindazoles has been synthesized. Reactivity of the amino groups of these bicyclic systems has been investigated. The halogenated pyrazolo-1,5-benzodiazepinones have been synthesized by the condensation of 7-aminoindazoles with ethyl acetoacetate.